Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2449-2462
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2449
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2449
Table 1 Programmed death-1 inhibitors in the fruquintinib plus programmed death-1 inhibitor and regorafenib plus programmed death-1 inhibitor group, n (%)
| PD-1 inhibitors | FP | RP |
| Camrelizumab | 28 (29.5) | 53 (65.5) |
| Sintilimab | 45 (47.4) | 18 (22.2) |
| Tislelizumab | 9 (9.5) | 1 (1.2) |
| Nivolumab | 1 (1.0) | 7 (8.6) |
| Toripalimab | 10 (10.5) | 2 (2.5) |
| Pembrolizumab | 2 (2.1) | 0 (0.0) |
- Citation: An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2449-2462
- URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2449.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2449